Chang Joe Y, Roth Jack A
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-0097, USA.
Thorac Surg Clin. 2007 May;17(2):251-9. doi: 10.1016/j.thorsurg.2007.03.011.
Image-guided SBRT with the delivery of a BED greater than 100 Gy is feasible and safe in the treatment of peripherally located inoperable stage I NSCLC. The 3- to 5-year local control and overall survival rates for SBRT seem to be much better than the rates for conventional radiotherapy, and the toxicity rate is minimal. Particularly for stage Ia (T1N0M0) disease, survival rates with SBRT were comparable with rates seen with surgical resection. SBRT is becoming the standard treatment for inoperable stage I NSCLC. Its role in operable stage I NSCLC. however. is not clear. To balance improved targeting accuracy with minimized treatment-related toxicity. a reliable immobilization device and consideration of image-guided tumor motion are crucial. The optimal dose regimen remains unclear, but a BED greater than 100 Gy seems warranted.
对于外周型不可手术的Ⅰ期非小细胞肺癌（NSCLC），实施生物等效剂量（BED）大于100 Gy的图像引导立体定向体部放疗（SBRT）是可行且安全的。SBRT的3至5年局部控制率和总生存率似乎远优于传统放疗，且毒性率极低。特别是对于Ⅰa期（T1N0M0）疾病，SBRT的生存率与手术切除相当。SBRT正成为不可手术的Ⅰ期NSCLC的标准治疗方法。然而，其在可手术的Ⅰ期NSCLC中的作用尚不清楚。为了在提高靶向准确性与将治疗相关毒性降至最低之间取得平衡，可靠的固定装置以及对图像引导下肿瘤运动的考虑至关重要。最佳剂量方案仍不明确，但BED大于100 Gy似乎是合理的。
